Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

POPCORN Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumors

Coordinator
Universidad De Navarra, Spain
Runs
1 May 2025 to 31 October 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101212926

What the project is doing

In the project's own words, from its summary on CORDIS.

Diffuse Midline Gliomas (DMGs) are the most aggressive pediatric brain tumors in desperate need of curative treatment. The median life expectancy of these children remains below 14 months after diagnosis, and nearly none survive beyond the second year. Similarly, for other high-risk pediatric brain tumors, there is hardly any option after recurrence, and long-term survivors are faced with life-long sequelae that impact their quality of life.

In this scenario, there is an urgent need for innovative, efficacious, and safe therapies for these patients. Oncolytic viruses are promising anticancer biotherapeutic agents that offer a unique combination of safety profile, direct antineoplastic activity, and the induction of anti-tumor immune responses. Recently, a Phase I clinical trial showed that combining the oncolytic adenovirus Delta-24-RGD and radiotherapy is non-toxic and results in anti-tumor responses and prolonged median overall survival (17.8 months) in patients.

However, results are still insufficient to be curative due to counteracting mechanisms intrinsic to the tumor microenvironment and also triggered by the virus that eventually exceeds its immunostimulatory properties. The proposed technology, termed “POPCORN”', is an oncolytic-based platform capable of expressing immunomodulatory single-domain antibodies directed to intrinsic targets in these tumors. We will develop the POPCORN Proof of Concept using a state-of-the-art experimental approach and validate its safety and efficacy in vitro and relevant in vivo DMG models.

We will also perform IND-enabling studies and apply for PUMA/PRIME designation. Additionally, we will work on the IPR strategy, and a value proposition to develop and commercialize the POPCORN platform will be generated. We envision the POPCORN platform becoming a game changer in treating DMGs, providing a one-of-a-kind tool for eliminating these aggressive tumors that could be extensive to other difficult-to-treat pediatric brain tumors.

Topics

Who is involved

OrganisationCityCountryRole
Universidad De NavarraPamplonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI